WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-11 09:36 am Sale |
2023-11-30 | 13G | Aclaris Therapeutics, Inc. ACRS |
WELLINGTON MANAGEMENT CO LLP | 0 0.000% |
-7,372,601 (Position Closed) |
Filing |
| 2023-04-10 09:06 am Purchase |
2023-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
WELLINGTON MANAGEMENT CO LLP | 7,372,601 11.050% |
1,888,588 (+34.44%) |
Filing |
| 2023-02-06 2:43 pm Sale |
2022-12-30 | 13G | Aclaris Therapeutics, Inc. ACRS |
WELLINGTON MANAGEMENT CO LLP | 5,484,013 8.220% |
-55,255 (-1.00%) |
Filing |
| 2022-02-04 09:12 am Purchase |
2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
WELLINGTON MANAGEMENT CO LLP | 5,539,268 9.050% |
5,539,268 (New Position) |
Filing |